An open label study to assess the safety and efficacy of COR-003 (2S 4R-Ketoconazole) in the treatment of Endogenous Cushing's syndrome

ID Number 14-0895

Principal Investigator(s)
Eliza B Geer

Department(s) or Division(s)
Endocrinology, Diabetes and Bone Disease


The purpose of this clinical research study is to test the effects of this experimental new drug COR-003 on people with Cushing's syndrome by measuring the cortisol levels in the urine and to see if there is any harm caused when using COR-003.

Contact Information
Yelena Lalazar
(212) 241-2613

Recruiting Patients: No